Holen Sie sich die Stockscreener-App
2.805
0.36%
-0.005
Schlusskurs vom Vortag:
$2.81
Offen:
$2.81
24-Stunden-Volumen:
412.91K
Relative Volume:
0.26
Marktkapitalisierung:
$208.52M
Einnahmen:
$6.96M
Nettoeinkommen (Verlust:
$-46.51M
KGV:
-16.35
EPS:
-0.1716
Netto-Cashflow:
$-37.99M
1W Leistung:
+0.36%
1M Leistung:
+11.11%
6M Leistung:
-25.93%
1J Leistung:
-20.68%
1-Tages-Spanne:
$2.65
$2.835
1-Wochen-Bereich:
$2.645
$2.96
52-Wochen-Spanne:
$1.60
$5.3881
Perspective Therapeutics Inc Stock (CATX) Company Profile
Firmenname
Perspective Therapeutics Inc
Sektor
Branche
Telefon
509-375-1202
Adresse
350 Hills Street, Suite 106, Richland
Vergleichen Sie CATX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.805 | 208.89M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
125.44 | 219.41B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.62 | 145.84B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.45 | 140.43B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
97.47 | 126.52B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.06 | 49.08B | 5.88B | 1.34B | 799.60M | 2.3489 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-10-10 | Eingeleitet | BTIG Research | Buy |
| 2025-03-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-01 | Eingeleitet | Wedbush | Outperform |
| 2024-09-25 | Eingeleitet | Truist | Buy |
| 2024-07-25 | Eingeleitet | BofA Securities | Buy |
| 2024-05-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten
Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data - TipRanks
Perspective Therapeutics Presents Updated Interim Data of - GlobeNewswire
Will Perspective Therapeutics Inc. stock attract ESG investorsEarnings Recap Summary & Weekly High Potential Stock Alerts - ulpravda.ru
Why Perspective Therapeutics Inc. stock could see breakout soonQuarterly Earnings Report & Verified Swing Trading Watchlists - ulpravda.ru
Published on: 2026-01-08 23:03:38 - ulpravda.ru
Will Perspective Therapeutics Inc. stock continue upward momentum2025 Biggest Moves & Reliable Entry Point Alerts - ulpravda.ru
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of “Buy” by Brokerages - Defense World
Why Perspective Therapeutics Inc. stock remains a top recommendationFederal Reserve Announcements & Investor Community Interactions - bollywoodhelpline.com
Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Up 0.4%Should You Buy? - MarketBeat
Market Review: Will Perspective Therapeutics Inc stock continue upward momentumTrend Reversal & Risk Adjusted Buy and Sell Alerts - moha.gov.vn
Perspective Therapeutics (FRA:AAJ0) EV-to-OCF : -0.36 (As of Dec. 26, 2025) - GuruFocus
Aug Decliners: How Perspective Therapeutics Inc AAJ0 stock benefits from digital adoption2025 Stock Rankings & Daily Stock Trend Watchlist - moha.gov.vn
Perspective Therapeutics Inc Stock Analysis and ForecastRisk Management Strategies & Affordable Portfolio Tips - earlytimes.in
Can Perspective Therapeutics Inc. stock resist market sell offsWeekly Investment Recap & Weekly Momentum Picks - Улправда
Aug EndMonth: What market sentiment indicators show for Perspective Therapeutics Inc. (AAJ0) stockWeekly Profit Recap & Proven Capital Preservation Methods - Улправда
Perspective Therapeutics Earnings Notes - Trefis
How Perspective Therapeutics Inc. stock valuations compare to rivalsMarket Trend Review & Weekly Watchlist for Consistent Profits - Улправда
Published on: 2025-12-20 05:01:39 - Улправда
Market Review: What market sentiment indicators show for Perspective Therapeutics Inc. (AAJ0) stockQuarterly Growth Report & Low Risk High Win Rate Stock Picks - Улправда
Trading Recap: How Perspective Therapeutics Inc. stock valuations compare to rivals2025 Support & Resistance & AI Powered Market Trend Analysis - Улправда
Is Perspective Therapeutics Inc. stock in correction or buying zone2025 Fundamental Recap & Growth Focused Stock Reports - DonanımHaber
How Perspective Therapeutics Inc. (AAJ0) stock benefits from digital adoptionInsider Selling & Precise Trade Entry Recommendations - DonanımHaber
How Perspective Therapeutics Inc. stock compares to market leadersEarnings Growth Report & Community Supported Trade Ideas - DonanımHaber
Should I buy Perspective Therapeutics Inc. stock before earnings seasonJuly 2025 Spike Watch & Smart Investment Allocation Insights - Улправда
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Perspective Therapeutics, Inc. (CATX) 6.37% in After-hours: Stock Rises Amid Increased Investor Engagement - Stocks Telegraph
EV Market: How strong is Perspective Therapeutics Inc stock earnings growthTrade Signal Summary & Precise Buy Zone Identification - moha.gov.vn
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of “Buy” from Brokerages - Defense World
Perspective Therapeutics Inc (CATX) Performance and Fundamentals Dashboard tells a completely different story - Setenews
What Is the Future of Remi Edelstahl Tubulars Limited Stock Expert Projections ExplainedCapital Gains Strategies & Maximize Gains Professionally - earlytimes.in
DHP India Limited Included in Top Momentum ScanRetail Trading Trends & Consistent Double Returns - earlytimes.in
What analysts say about Perspective Therapeutics Inc AAJ0 stockMorning Star Patterns & Download Your Free Wealth Map PDF - earlytimes.in
Affinity Asset Advisors LLC Decreases Holdings in Perspective Therapeutics, Inc. $CATX - Defense World
Perspective Therapeutics (NASDAQ: CATX) sees FMR disclose 0.4% stake - Stock Titan
Can Perspective Therapeutics Inc. stock sustain breakout momentumQuarterly Portfolio Report & High Accuracy Trade Signal Alerts - Newser
CATX SEC FilingsPerspective Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium - marketscreener.com
Perspective Therapeutics (NYSE: CATX) to Present VMT-α-NET Data at 2026 ASCO-GI - Stock Titan
How Perspective Therapeutics Inc. stock moves on employment dataEarnings Recap Summary & Growth-Oriented Investment Plans - Newser
Can Perspective Therapeutics Inc. stock ride next bull market cycle2025 Analyst Calls & AI Enhanced Trade Execution Alerts - Newser
Perspective Therapeutics Announces Acceptance of VMT-α-NET - GlobeNewswire
Is Perspective Therapeutics Inc. stock attractive for growth fundsWeekly Trend Summary & Weekly Watchlist for Consistent Profits - Newser
How Perspective Therapeutics Inc. stock reacts to oil pricesGlobal Markets & Expert Curated Trade Setup Alerts - Newser
How Perspective Therapeutics Inc. stock compares with market leadersQuarterly Trade Summary & Long-Term Safe Return Strategies - Newser
Why Perspective Therapeutics Inc. (AAJ0) stock is listed among top recommendationsWeekly Trend Report & Technical Entry and Exit Tips - Newser
What downside risks could hit Perspective Therapeutics Inc. (AAJ0) stockBull Run & Verified Stock Trade Ideas - Newser
How Perspective Therapeutics Inc. stock reacts to stronger dollarWeekly Risk Summary & Capital Efficient Trading Techniques - Newser
Does Perspective Therapeutics Inc. (AAJ0) stock trade below intrinsic value2025 Valuation Update & Risk Controlled Stock Pick Alerts - Newser
Perspective Therapeutics Updates Corporate Presentation on Advancements - TipRanks
Finanzdaten der Perspective Therapeutics Inc-Aktie (CATX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.54%
0.49%
Kapitalisierung:
|
Volumen (24h):